Thermo Fisher Scientific Specialty Diagnostics — Consolidated revenues increased by 4.0% to $1.17B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 4.0%, from $1.13B to $1.17B. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates strong market demand and successful product adoption, while a decrease signals market saturation or competitive pressure.
The total gross income generated from the sale of diagnostic products, reagents, and services within the Specialty Diagn...
Key performance indicator for all diagnostic equipment and consumable manufacturers.
tmo_segment_specialty_diagnostics_consolidated_revenues| Q2 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $1.24B | $1.48B | $1.10B | $1.10B | $1.10B | $1.10B | $1.10B | $1.13B | $1.17B |
| QoQ Change | — | +20.0% | -25.7% | +0.0% | +0.0% | +0.0% | +0.0% | +2.5% | +4.0% |
| YoY Change | — | — | -10.9% | -25.7% | +0.0% | — | — | +2.5% | +4.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.